Immunotherapy study opens for patients with triple negative breast cancer
December 15, 2017
Providence Cancer Institute is participating in a nationwide clinical trial of the immunotherapy pembrolizumab (Keytruda) for patients with triple negative breast cancer. Pembrolizumab is FDA approved for several other types of cancer. It works by interfering with PD-1, a protective mechanism on the surface of cancer cells, so that the immune system can destroy those cancer cells. The study will compare the safety and effectiveness of pembrolizumab plus chemotherapy, versus chemotherapy alone, to determine whether the combination improves outcomes for patients with triple negative breast cancer.
View the study here.
28 breast cancer studies are currently open
This study is one of 28 ongoing research studies investigating a broad spectrum of breast cancer therapies and interventions at Providence Cancer Institute. We offer studies aimed at improving cure rates, quality of life and survival for both early-stage and metastatic breast cancer patients. These studies range from small phase I clinical trials to larger international studies, including studies from the National Cancer Institute, our own NCI Community Oncology Research Program (the Pacific Cancer Research Consortium), and pharmaceutical industry partners. Our own investigator-initiated research studies, available exclusively at Providence Cancer Institute, focus on novel approaches that harness the immune system to treat cancer.
New research studies are added frequently. For a complete list of all current breast cancer studies at Providence Cancer Institute, please visit our website. For more information, call our Clinical Trials office at 503-215-2614.
A team of breast cancer specialists
The research team at the Earle A. Chiles Research Institute at Providence Cancer Institute includes oncologists who specialize exclusively in breast cancer, as well as breast-cancer-focused research nurses, laboratory scientists, data coordinators and lab assistants. Every person on this team is passionate about providing the best possible care and the best available study options for patients with breast cancer.